Guggenheim Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $16

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $16.